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KESAN GELUCIRE® 44/14 TERHADAP BIOKEPEROLEHAN ORAL BAGI 
CICLOSPORIN A 
 
ABSTRAK 
 
Kajian ini dijalankan untuk mengkaji kesan Gelucire® 44/14 terhadap 
biokeperolehan oral bagi satu drug polipeptida lipofilik model, ciclosporin A. 
Formulasi Gelucire® 44/14 mengandungi ciclosporin A dengan nisbah drug 
kepada Gelucire® 44/14 1:4, 1:10, 1:14 dan 1:20 telah berjaya disediakan 
melalui teknik lebur-fusi. Kajian-kajian in vitro menunjukkan keterlarutan air and 
pelarutan bagi ciclosporin A meningkat secara berkadar langsung dengan 
jumlah Gelucire® yang digunakan dalam formulasi. Semua formulasi dapat 
membentuk produk emulsi yang stabil apabila dimasukkan ke dalam medium 
berakueus. Tambahan pula, apabila dimasukkan ke dalam medium berakueus, 
formulasi dengan nisbah ciclosporin A kepada Gelucire® 44/14 1:10, 1:14 dan 
1:20 dapat membentuk produk emulsi yang mempunyai saiz titisan yang 
standing dengan formulasi yang Gelucire® 44/14 sahaja. Penambahan 
ciclosporin A ke dalam Gelucire® 44/14 juga tidak mengubah suhu peleburan 
tersebut. 
 
Satu kaedah kromatografi cecair-spektrometri jisim bertandem telah berjaya 
dibangunkan untuk penentuan kepekatan ciclosporin A dalam plasma. Kaedah 
tersebut adalah ringkas, peka, dapat dihasilkan semula serta spesifik dan telah 
digunakan untuk menilai biokeperolehan formulasi ciclosporin A dalam 
Gelucire® 44/14. 
 xx
Dalam kajian in vivo yang melibatkan penggunaan tikus Sprague-Dawley, 
formulasi yang bernisbah drug kepada Gelucire® 44/14 pada 1:10 dapat 
meningkatkan biokeperolehan oral ciclosporin A sebanyak 2.8 kali ganda 
berbanding dengan ampaian berakueus drug, dan setanding dengan satu 
formulasi pengemulsian kendiri yang diperolehi secara komersial, Sandimmun 
Neoral®. 
 
Sebagai kesimpulan, Gelucire® 44/14 dapat meningkatkan keterlarutan satu 
drug polipeptida lipofilik iaitu ciclosporin A dan seterusnya meningkatkan 
biokeperolehan oral drug tersebut. Dengan itu, Gelucire® 44/14 boleh dijadikan 
satu eksipien yang berguna dalam formulasi pengemulsian kendiri untuk 
meningkatkan biokeperolehan oral drug-drug berlipofilik. 
 
 xxi
EFFECT OF GELUCIRE® 44/14 ON THE ORAL BIOAVAILABILITY OF 
CYCLOSPORIN A 
 
ABSTRACT 
 
The present study was conducted to investigate the effect of Gelucire® 44/14 on 
the oral bioavailability of a model lipophilic polypeptide drug, cyclosporin A. 
Gelucire® 44/14 formulations of cyclosporin A at drug to Gelucire® 44/14 ratios 
of 1:4, 1:10, 1:14 and 1:20 (w/w) were successfully prepared using a heat-
fusion method. In vitro studies showed that the aqueous solubility and 
dissolution of cyclosporin A were proportionally increased with the amount of 
Gelucire® used in the formulations. All formulations prepared could form stable 
emulsion products when introduced into an aqueous medium. Moreover, upon 
introduction into an aqueous medium, formulations with 1:10, 1:14 and 1:20 
ratios of cyclosporin A to Gelucire® 44/14 formed emulsion products with 
comparable droplet sizes to that using Gelucire® alone. Additionally, 
incorporation of cyclosporin A into Gelucire® 44/14 did not alter the melting point 
of the base. 
 
A liquid chromatography tandem mass spectrometry method was successfully 
developed for the determination of plasma concentrations of cyclosporin A. The 
method was simple, sensitive, reproducible and specific and was applied to 
evaluate the bioavailability of the 1:10 formulation of cyclosporin A in Gelucire® 
44/14. 
 
 xxii
The in vivo study conducted using Sprague-Dawley rats revealed that at a drug 
to Gelucire® ratio of 1:10, the formulation was capable of increasing the oral 
bioavailability of cyclosporin A by approximately 2.8-fold compared to an 
aqueous suspension of the drug and comparable to that of a commercially 
available self-emulsifying formulation, Sandimmun Neoral®. 
 
In conclusion, Gelucire® 44/14 enhanced the solubility of a lipophilic polypeptide 
drug, cyclosporin A, and subsequently increased the oral bioavailability of the 
drug. Thus Gelucire® 44/14 could be a useful excipient in self-emulsifying 
formulations for enhancing the oral bioavailability of lipophilic drugs. 
CHAPTER 1 
INTRODUCTION 
 
1.1 SELF-EMULSIFYING DRUG DELIVERY SYSTEMS (SEDDS) 
1.1.1 INTRODUCTION 
The oral route is the preferred route of drug delivery because of its simplicity 
and convenience. However, oral absorption of some drugs is limited due to their 
unfavourable physiochemical properties. Nearly 40% of new drug candidates 
exhibit low solubility in water which leads to poor oral bioavailability, high intra- 
and inter-subject variability and lack of dose proportionality (Robinson, 1996). 
One of the approaches to enhance the oral bioavailability of poorly water 
soluble drugs is to incorporate the lipophilic drugs into lipid delivery systems, 
such as surfactant dispersions (González et al., 2002), emulsions (Kim et al., 
2002), liposomes (Lee et al., 1999), lecithin vesicles (Guo et al., 2001) and self-
emulsifying drug delivery systems (Odeberg et al., 2003). 
 
Self-emulsifying drug delivery systems (SEDDS) are defined as isotropic 
mixtures of natural or synthetic oils, solid or liquid surfactants, one or more 
hydrophilic solvents and co-solvents which will form oil-in-water (o/w) emulsions 
instantaneously upon introduction into aqueous phase under gentle agitation 
(Pouton, 1985; Constantinides, 1995; Gursoy and Benita, 2004). Enhanced 
absorption of poorly bioavailable drugs can be achieved by presenting the drugs 
in small droplets of oil when the formulation emulsifies rapidly in the aqueous 
contents of the stomach. SEDDS are different from the conventional emulsion 
systems wherein the latter have several disadvantages such as their inherent 
physical instability upon storage, the inconveniences due to their large volume 
and also poor precision of dosing (Humberstone and Charman, 1997). 
 
SEDDS are usually formulated as oily formulations and they are encapsulated 
in soft gelatin capsules. They can also appear in the form of semi-solid when 
semi-solid oils or solid surfactants are employed in their formulation. These 
semi-solid formulations are encapsulated in hard gelatin capsules and they 
differ from the oily self-emulsifying formulations only in the physical appearance. 
 
1.1.2 EXCIPIENTS USED IN SEDDS 
Self-emulsifying drug delivery systems comprise oils, surfactants and solvents 
or co-solvents. There is a large variety of excipients available for the formulation 
of SEDDS, ranging from natural or synthetic oils, solid and liquid surfactants 
with varying hydrophilicity as well as co-solvents with varying solvation capacity. 
To formulate satisfactory SEDDS, the combinations as well as ratios of 
excipients employed are of utmost importance. 
 
(a) OILS 
Oil is an important component in the formulation of SEDDS. It is used as a 
carrier to dissolve the lipophilic drug. Naturally-derived oils are not frequently 
used as the oil fraction in SEDDS due to their poor ability to dissolve a large 
amount of lipophilic drug (Gursoy and Benita, 2004). Thus, synthetic or 
chemically modified oils, such as hydrolyzed vegetables oils are widely used in 
SEDDS. Besides having better drug solubility properties, chemically modified 
oils also have better ability to facilitate self-emulsification because they possess 
surfactant properties of their own (Constantinides, 1995; Hauss et al., 1998). 
Medium chain triglycerides were frequently used in earlier work to formulate 
SEDDS because of their higher fluidity, better solubility properties and self-
emulsification ability (Charman et al., 1992; Shah et al., 1994). However, they 
have become less attractive when novel semi-synthetic oils with amphiphilic 
properties were introduced, such as the polyglycolized glycerides with varying 
fatty acid and polyethylene glycol chain lengths (Constantinides, 1995). In a 
study by Devani et al. (2004), which investigated the self-emulsification 
properties of six different types of polyglycolized glycerides, it was observed 
that C8/C10 polyglycolized glycerides (Labrasol) with the highest HLB value of 
14 displayed the most satisfactory self-emulsification properties. 
 
(b) SURFACTANTS 
Surfactants or surface-active agents are amphiphilic molecules and consist of 
both hydrophilic and lipophilic parts. They are used to facilitate the self-
emulsification process of the SEDDS, which in turn help to improve or increase 
the bioavailability of poorly absorbable drugs. The mechanisms involved are 
complex and were described by Constantinides (1995) as “diffusion and 
stranding”. 
 
Surfactants are classified according to their hydrophile-lipophile balance (HLB) 
values. This HLB value indicates the hydrophilicity of surfactants wherein 
surfactants which are more hydrophilic possess higher HLB values. O/w 
emulsions can be formed using surfactants which have HLB values in the range 
of approximately 8-18 (Constantinides and Scalart, 1997). It was reported that 
surfactants with high HLB values will provide rapid emulsification, with excellent 
spreading properties and rapid cloud formation, leading to the formation of very 
fine o/w droplets (Gursoy and Benita, 2004). 
 
Selection of the type of surfactant to be used in the formulation of SEDDS will 
depend on factors such as its emulsification performance, safety as well as the 
stability of the emulsion formed upon contact with aqueous medium. Naturally-
derived surfactants are safe to consume but they display limited self-
emulsification capacity. As for synthetic surfactants, non-ionic surfactants are 
widely recommended as compared to ionic surfactants because the former are 
less toxic. To form stable SEDDS, the concentration of surfactants to be used 
was suggested to be within the range of 30% to 60% (w/w) (Gershanik and 
Benita, 2000; Gursoy and Benita, 2004). The amount of surfactants to be used 
is critical as too large an amount may cause irritation of the gastrointestinal tract 
while insufficient amount of surfactants used may compromise the self-
emulsification ability of SEDDS. 
 
Surfactants commonly used in SEDDS are emulsifiers which include solid or 
liquid ethoxylated polyglycolized glycerides and polyoxyethylene 20 oleate 
(polysorbate 80) (Gursoy and Benita, 2004). Pouton (1982) and Wakerly (1986) 
screened a wide range of industrial non-ionic surfactants and found that the 
most efficient SEDDS could be formulated using surfactants with predominantly 
unsaturated acyl chains. Amongst these, the most efficient were oleates with 
HLB value of approximately 11. 
 
(c) SOLVENTS/CO-SOLVENTS 
Solvents/co-solvents are added into SEDDS to increase the solvent capacity of 
the formulations especially in those which contain a large amount (30% - 60%) 
of hydrophilic surfactants (Gershanik and Benita, 2000). High solvent capacity is 
required in SEDDS to dissolve large amount of lipophilic drugs or hydrophilic 
surfactants. Organic solvents such as propylene glycol and polyethylene glycol 
are normally used as they are safe for human consumption. However, alcohols 
and other volatile solvents may not be suitable because such solvents will 
migrate into the shell of hard and soft gelatin capsules, resulting in the 
precipitation of the lipophilic drugs (Gursoy and Benita, 2004). 
 
1.1.3 MECHANISM OF SELF-EMULSIFICATION 
To date, the mechanism of self-emulsification is yet to be fully elucidated. 
According to Reiss (1975), emulsification occurs when the entropy change that 
favours dispersion is greater than the free energy required to increase the 
surface area between the oil and aqueous phases of the dispersion. The 
change in free energy (∆G) associated with the process of emulsification, 
ignoring the free energy of mixing, can be expressed by 
∆G = ∑
i
 Ni4πri2σ  (1.1) 
Ni is the number of droplets of radius ri whereas σ is the interfacial energy. Self-
emulsification will occur spontaneously only when the interfacial energy is low. 
However, emulsions are not thermodynamically stable as the oil phase and the 
aqueous phase will tend to separate with time to reduce the interfacial area and 
also free energy of the system. Therefore, the presence of emulsifiers will help 
to reduce interfacial tensions by forming a barrier around the oil droplets and 
hence the free energy of the systems. 
 
On the other hand, Groves et al. (1974) related emulsification with the formation 
of liquid crystalline phase. Liquid crystalline phase is the phase between liquid 
and crystal phase. A liquid crystal has both the properties of a crystal as well as 
liquid. When additional energy is exerted onto the liquid crystalline phase, it will 
turn into liquid phase. For self-emulsifying systems, when the oil phase is 
introduced into the aqueous phase with gentle agitation, the aqueous phase will 
penetrate through the interface into oil phase until the interface of the two 
phases is disrupted. Consequently, oil droplets are formed resulting in 
emulsification. Thus, the ease of emulsification is governed by the ease of water 
penetration into the various liquid crystal or gel phases formed on the surface of 
droplets. The liquid crystal formation surrounding the oil droplets will increase 
the stability of the emulsion. Nevertheless, the relationship between liquid 
crystal formation and emulsion formation could be more complicated as it 
appeared to be (Craig et al., 1995). Various factors can affect the process of 
self-emulsification, such as the nature of oil/surfactant pair, the surfactant 
concentration used as well as the temperature at which self-emulsification 
occurs (Gursoy and Benita, 2004). Moreover, the presence of drug compound 
will alter the emulsion characteristics, probably by interacting with the liquid 
crystalline phase (Craig, 1993). 
 
 
 
1.1.4 CHARACTERIZATION OF SEDDS 
Various approaches have been used to characterize SEDDS. Gursoy and 
Benita (2004) suggested that SEDDS could be characterized using the rate of 
emulsification, distribution of droplet size as well as polarity and charge of 
emulsion droplets formed. Groves and Mustafa (1974) measured the 
spontaneity of self-emulsification of oils by determining the rate of emulsification. 
Later, when Pouton (1984, 1985) investigated the emulsification efficiency of 
various compositions of Tween 85/medium-chain triglyceride systems, it was 
suggested that the particle size of the droplets formed was more important than 
emulsification rate for the assessment of emulsification efficiency. It is well 
known that the particle size of emulsion droplets formed will determine the rate 
and extent of drug release and subsequently affect the oral absorption of the 
drug. For this reason, Pouton (1985) suggested that the efficiency of SEDDS 
should be characterized by both emulsification rate and particle size distribution 
of emulsion products formed.  
 
Formulations with small emulsion droplet size generally could increase the oral 
bioavailability of the drugs incorporated. It is because the small droplet size 
provides a large interfacial surface area for drug absorption (Charman et al., 
1992; Shah et al., 1994). Khoo et al. (1998) pointed out that SEDDS typically 
produce emulsions with particle size ranging between 100 and 300 nm whilst 
transparent microemulsions will be formed when the particle size of the 
emulsion droplets is less than 100 nm. The droplet size of an emulsion is 
normally measured using laser diffraction method or photon correlation 
spectrometry method. The former method is used to measure droplet size in 
micrometer size range whereas the latter is used to determine droplet size in 
nanometer size range. However, Devani et al. (2004) have highlighted the 
difficulties associated with the measurement of particle size for SEDDS. As the 
emulsion has to be diluted during the measurement, this would lead to a 
reduction in droplet size and an increase in the width of the size distribution. 
Therefore, low aqueous dilutions and a standardized method should be 
employed when measuring the emulsion droplet size in order to minimize 
inadvertent over-reduction of the droplet size and disparity between data sets. 
 
Besides having the ability to form an emulsion with fine particles, Shah et al. 
(1994) pointed out that the SEDDS performance is also governed by the polarity 
of the resulting droplets. Favourable polarity permits an acceptable rate of drug 
release into the aqueous phase. The HLB value, chain length and degree of 
unsaturation of the fatty acid, molecular weight of the hydrophilic portion and 
concentration of the emulsifier have an impact on the polarity of the oil droplets 
(Shah et al., 1994; Gursoy and Benita, 2004). 
 
The presence of free fatty acids in the oil phase can cause the emulsion 
droplets formed to be negatively charged. It has been shown in some studies 
that positive charged emulsion droplets undergo electrostatic interaction with 
monolayer of Caco-2 cells and also the mucosal surface of everted rat intestine 
(Gershanik et al., 1998; Gershanik et al., 2000). Furthermore, positive charged 
droplets were observed to enhance the oral bioavailability of progesterone and 
producd higher blood levels of cyclosporin A compared to those with negative 
charge (Gershanik and Benita, 2000). Therefore, addition of a cationic lipid, 
such as oleylamine, into the SEDDS formulation will produce a positive charged 
system which could facilitate the absorption of drugs. 
 
1.1.5 IMPROVEMENT OF ORAL ABSORPTION BY SEDDS 
Many studies have been conducted to investigate the potential of SEDDS in 
enhancing the oral absorption of poorly water soluble drugs. Tested using 
beagle dogs, the oral bioavailability of an antimalarial drug, halofantrine, was 
found to increase 6-fold when administered using a medium chain triglyceride 
SEDDS formulation compared to a tablet formulation of its hydrochloride salt 
(Khoo et al., 1998). 
 
Kim and Ku (2000) reported that the oral bioavailability of indomethacin in rats 
was markedly increased when administered as a SEDDS compared to a 
methylcellulose suspension of the drug. The increase in bioavailability was 
attributed to an increase in the water solubility of the drug when formulated as a 
SEDDS. More recently, Araya et al. (2005) reported a versatile novel SEDDS 
formulation which could enhance the oral bioavailability of poorly water soluble 
compounds by increasing their aqueous solubility. The aqueous solubility of six 
poorly water soluble drugs, namely ibuprofen, ketoprofen, tolbutamide, AG-
041R, BO-653 and ER-1258, were shown to increase by 340 to 98000 folds 
when formulated using the SEDDS. Moreover, the oral bioavailability of the 
drugs was found to be equivalent to that of a solution or an o/w emulsion. 
Compared to normal aqueous suspensions of the drugs, the oral bioavailability 
was increased by 1.5 to 78 times. 
 
In summary, SEDDS formulations could be utilized to improve the oral 
bioavailability of poorly water soluble drugs by presenting the drugs in a 
solubilized form within the oil phase which self-emulsifies in the gastrointestinal 
tract to form fine oil droplets. 
 
1.2 GELUCIRE® 
1.2.1 INTRODUCTION 
Gelucire® is a family of glyceride-based excipients which has been widely used 
as controlled release matrices and also for enhancing the oral bioavailability of 
drugs. It is amphiphilic, being composed of a mixture of glycerides (hydrophobic) 
and polyethylene glycol (PEG) ester of fatty acids (hydrophilic). Gelucire® is a 
semi solid waxy material which is inert, safe and non-toxic. It is derived from 
natural food-grade fats and oils and has been reported to be chemically stable 
to both temperature and humidity up to 50°C and 80% RH (Remunan et al., 
1992). 
 
Generally, Gelucire® is synthesized through an alcoholysis reaction wherein 
PEG (usually of molecular weight range between 300–1500) is reacted with 
hydrogenated vegetable oils (such as coconut, palm or palm kernel oil) at 
230 °C under a nitrogen environment. Besides alcoholysis, Gelucire® can also 
be manufactured through the direct esterification of fatty acids (of coconut oils, 
palmitic acid or stearic acid) with glycerol and PEG. A wide range of Gelucire® 
grades is produced from the different degrees of esterification, and the 
specification of each grade of the bases is showed in Table 1.1 (Craig, 1995). 
 
Gelucire® is identified by two values, the first referring to the nominal melting 
point of the base and the second to the HLB value. The nominal melting point 
which ranges from 33°C to 70°C can only be used as a reference and does not 
represent the accurate melting point of the base. It is because each Gelucire® 
grade contains a mixture of many different components and as a result, it does 
not posses a single, sharp melting point. The melting point of Gelucire® can 
influence the release of the incorporated drug from the base. In the formulation 
of fast release dosage forms, Gelucire® grades with lower melting points are 
preferred. On the other hand, those with higher melting points are suitable for 
controlled release formulations. For example, Gelucire® 35/10 (Vicente et al., 
2000) and Gelucire® 44/14 (Dennis et al., 1990) have been used to formulate 
fast release formulations whereas controlled release formulations have been 
prepared using Gelucire® 50/13 (Vippagunta et al., 2002) and Gelucire® 64/02 
(Charro and Jato, 1992). The release rate of potassium chloride from various 
Gelucire® bases has been investigated by Wu et al. (2002). They found that the 
release rate of potassium chloride was increased in the following order of the 
Gelucire® grades, namely 62/05, 53/10, 48/09, 46/07 and 44/14. 
 
The HLB value of Gelucire® ranges from 1 to 18. It represents the hydrophilicity 
of the Gelucire® base and corresponds to the ratio of glycerides to the PEG 
esters in the base. Gelucire® bases with higher HLB values in general contain 
high portions of hydrophilic fractions (polyethylene glycol esters) than lipophilic 
fractions (glycerides) and are suitable for preparing fast release formulations. In 
contrast, Gelucire® bases with lower HLB values have higher portions of 
lipophilic fractions and are suitable for formulating controlled release 
formulations. Dennis et al. (1990) observed that Gelucire® 50/13 released 
ketoprofen too rapidly to be useful for preparation of sustained release 
formulations. Gelucire® 50/02, another grade of Gelucire® which has the same 
melting point but different HLB value, was successfully used to prepare a 
controlled release formulation containing sodium salicylate (Aïnaoui and 
Vergnaud, 1998). Nevertheless, a mixture of two Gelucire® bases could be used 
to provide the desired lipophilicity. Dennis et al. (1990) prepared a controlled 
release formulation containing ketoprofen using a mixture of Gelucire® 50/13 
and 50/02 at a ratio of 3:1 (w/w). The mixture has a final HLB value of 10.25. 
 
1.2.2 GELUCIRE® 44/14 (G44/14) 
Gelucire® 44/14 has a nominal melting point of 44°C and a HLB value of 14. It is 
derived from reacting hydrogenated palm kernel oil with PEG 1500. Gelucire® 
44/14 consists of approximately 20% mono-, di- and triglycerides, 72% mono- 
and di- fatty acid esters of PEG 1500 and 8% free PEG 1500 (Gattefossé, 
1999). The distribution of its fatty acids is shown in Table 1.2. Gelucire® 44/14 is 
an ideal excipient in self-emulsifying formulations due to its unique balance of 
short, medium and long chain fatty acids in the base (Gattefossé, 1999). It will 
form an exceptionally stable and fine dispersion when in contact with 
gastrointestinal fluids at body temperature (~37 °C). 
 
Many workers have investigated the ability of Gelucire® 44/14 to promote rapid 
drug release and bioavailability via fast release formulations or self-emulsifying 
formulations. They have been reports of marked improvements in solubility, 
dissolution rate and bioavailability of poorly water soluble drugs when 
formulated with Gelucire® 44/14. Yüksel et al. (2003) and Karataş et al. (2005) 
showed that the solubility and dissolution rate of piroxicam could be increased 
by formulating piroxicam as a semi-solid dispersion using Gelucire® 44/14 and 
Labrasol. These workers claimed that the increased dissolution of the drug from 
the semi solid dispersion could be attributed to a partial dissolution of the drug 
in the excipients, solubilization effects of Gelucire® 44/14 and Labrasol, as well 
as improved wettability of the preparation. 
 
Schamp et al. (2006) found that a semi-solid lipid formulation of EMD 50733 
using Gelucire® 44/14 with a solubilizing agent (2-vinylpyrrolidone) gave the 
best results with respect to dissolution, stability upon storage and bioavailability. 
They also concluded that to achieve adequate and reliable dissolution of poorly 
soluble drugs in vivo, lipid excipients used should not only have appropriate 
solubilizing properties for the drug in the formulation, but should also assist in 
maintaining the drug in solution during release in the gastrointestinal tract. It has 
been shown that the presence of Gelucire® 44/14 was able to prevent 
precipitation of EMD 50733 even during an extended dissolution period of 3 
hours. 
 
Gelucire® 44/14 can also be used to administer high doses of lipophilic drugs, 
for example DMP 323 (a HIV protease inhibitor) (Aungst et al., 1997), without 
compromising oral bioavailability. When the solubility limit of DMP 323 in the 
gastrointestinal fluids is reached, increasing the dose results in decreased 
fraction of dose absorbed. It has been revealed that Gelucire® 44/14 improved 
DMP 323 solubility in dilute aqueous solution. In addition, Aungst et al. (1997) 
also stated that amphiphilic vehicles with lower HLB values were much less 
effective solubilizing agents.  
 
Moreover, Barker et al. (2003) had successfully prepared a dispersion of α-
tocopherol in Gelucire® 44/14 which had dual advantages, namely incorporation 
of a liquid drug in a solid dosage form and improved bioavailability of the drug. 
The workers pointed out that the increase in bioavailability might be at least 
partially associated with emulsification or disintegration of Gelucire® 44/14 on 
contact with water, with evidence obtained that the drug was incorporated into 
the hydration layer of the Gelucire®. 
 
Gelucire® 44/14 can also be formulated as solid oral dosage forms. This semi 
solid base could be processed into a powder form such as pellets, tablets and 
hard capsules (Newton et al., 2001). Chambin et al. (2004) produced a solid 
oral dosage form of Gelucire® 44/14 using cryogenic grinding. Gelucire® 44/14 
was successfully prepared in powder form and the cryogenic grinding process 
did not modify the physical properties, self-emulsifying capacity or dissolution 
performance of the formulation tested which was made of Gelucire® 44/14 and 
ketoprofen at a ratio of 90:10. 
 
1.3 CYCLOSPORIN A (CsA) 
1.3.1 INTRODUCTION 
 
Figure 1.1 Chemical structure of cyclosporin A  
 
Cyclosporin A is a hydrophobic cyclic undecapeptide with a molecular formula 
of C62H111N11O12. The molecular weight of cyclosporin A is 1202.6 g/mol. It is 
chemically designated as [R-[R*,R*-(E)]]-cyclic(L-alanyl-D-alanyl-N-methyl-L-
leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-
octenoyl-L-α-amino-butyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-
L-leucyl). Cyclosporin A consists of 11 amino acids, including several N-
methylated amino acids and the nonproteinogenic amino acids L-2-aminobutyric 
acid, (4R)-4-[(E)-2-butenyl]-4-methyl-L-threonine, and D alanine. It is also 
known as ciclosporine in Europe and exists as white prismatic crystals. 
Cyclosporin A is poorly soluble in water with an aqueous solubility of 27.67 
μg/ml at 25 °C (Ismailos et al., 1991; Alfred, 1993) and a log P value of 2.92 
(Taylor et al., 1993). Cyclosporin A possesses good permeability through the 
gastrointestinal membrane and is a Class II drug according to the 
Biopharmaceutics Classification System (BCS) (Amidon et al., 1995).  
 
Cyclosporin A is isolated from the fungus Tolypocladium inflatum Gams. 
Several reports have stated the isolation of cyclosporine from other fungal 
metabolites of the fungi Tolypocladium inflatum Gams (Dreyfuss et al.,1976; 
Traber et al., 1977a; Traber et al., 1977b; Traber et al., 1982). Biosynthesis and 
synthesis of cyclosporin A have also been investigated by various researchers 
(Wenger, 1982; Wenger, 1983a; Wenger, 1983b; Zocher et al., 1984). 
Discovery of cyclosporin began a new era in immunopharmacology. It is utilized 
clinically for immunomodulation such as prevention of rejection following 
transplantation of kidney, liver, bone marrow and pancreas (Matzke and  Luke, 
1988). Cyclosporin A is also used to delay or prevent disease progression in 
patients with autoimmune disease and inflammation (Miller et al., 1992; Tibell 
and Norrlind, 1994; Noble and Markham, 1995). The immunosuppressive effect 
of cyclosporin A is due to a selective and reversible inhibition of T-lymphocytes 
(Ferron et al., 1998). Cyclosporin A selectively inhibits interleukin-2 (IL-2) driven 
proliferation of activated T-lymphocytes. 
 
In spite of the usefulness of cyclosporin A, its extended usage has often been 
limited by several disadvantages including low bioavailability, narrow 
therapeutic window, nephrotoxicity and hepatotoxicity (Kahan, 1989; Yee and 
Saloman, 1992; Gijtenbeek et al., 1999). Nephrotoxicity may occur acutely, 
associated with reversible hemodynamic changes (Curtis and Laskow, 1988) or 
as a result of interstitial fibrosis after chronic dosing (Humes et al., 1985). 
 Cyclosporin A is administered either orally or intravenously. It has poor 
absorption after intramuscular administration (Keown et al., 1981) and was 
reported as a typical drug with the worst and non-regular absorption 
(Klompmaker et al., 1993). The oral absorption of cyclosporin A is slow and 
incomplete, regardless of in rats or in humans. The mean bioavailability is 
similar in rats and humans, which is about 30% of the administered dose (Ueda 
et al., 1984; Wagner et al., 1987; Kahan, 1989). The absorption site is the upper 
part of the small intestine and the mean time to get peak cyclosporin A blood 
level is around 4 hours (Margaret, 1989) but Kahan (1985) observed large inter-
patient variations with the mean time to get peak cyclosporin A blood level 
ranging between 1 and 8 hours in renal transplant patients. 
 
Margaret (1989) noted that gut motility, bile flow and food affect the absorption 
of cyclosporin A. Atkinson et al. (1984) pointed out that diarrhoea from any 
cause may reduce absorption of cyclosporin A sharply. The moderate increase 
in rate of gastric emptying induced by metoclopramide may increase the 
bioavailability of cyclosporin A (Wadhwa et al., 1987a, b). Ericzon et al. (1987) 
showed that the administration of bile salts increased cyclosporin A absorption 
in dogs. In other studies, cyclosporin A absorption was shown to be reduced by 
wine (Ota, 1983; Tsunoda et al., 2001) and slowed by a soybean nutritional 
supplement (Kahan, 1985) but increased by grapefruit juice (Yee et al., 1995). 
 
Due to the lipophilic nature of cyclosporin A, the drug accumulates in body fat. 
Waters et al. (1986) found that the area under the drug concentration/time curve 
correlated not with total body weight but with skinfold thickness. In animal 
experiments, cyclosporin A was found in liver, kidney, adrenals, pancreas, 
thymus, thyroid and renal fat after administration of 3H-cyclosporine (Hassan 
and Al-Yahya, 1987). Using intravenous tritiated cyclosporin, the heaviest 
accumulation of radiation was in the liver and, in descending order, fat, kidney, 
reticulo-endothelial and endocrine systems, and blood (Maurer et al., 1984). 
Another study revealed that from intravenous administration in human, 
cyclosporin A was found to be distributed according to a three-compartment 
distribution model (Hassan and Al-Yahya, 1987). 
 
Cyclosporin A is extensively metabolized in the liver (Maurer et al., 1984) and 
90% is eliminated in the bile whilst around 6% is eliminated in the kidney 
(Kahan, 1989). Only 1% of an oral dose is excreted unchanged in urine or bile. 
Cyclosporin A elimination follows first-order kinetics (Kahan, 1985). It has been 
estimated that as much as 50% of a dose of cyclosporin A may be extracted 
from the blood during its first passage through the liver. Although cyclosporin A 
has more than 30 metabolites which could be quantified analytically (Christians 
and Sewing, 1993), cyclosporin A is still found to be more toxic than these 
metabolites (Hassan and Al-Yahya, 1987). 
 
The first marketed oral formulation of cyclosporin A, Sandimmune® was 
formulated with olive oil, Labrafil (peglicol-5 oleate), and alcohol (Johnston et al., 
1986). This formulation will form a crude o/w emulsion upon dilution with an 
aqueous phase. Sandimmune® results in a comparatively low oral bioavailability 
along with a high inter-subject variability because of the presence of bile and 
pancreatin is mandatory in promoting the absorption of cyclosporin A (Metha et 
al., 1984; Friman and Bäckman, 1996). The mean absolute bioavailability of 
cyclosporin A is only approximately 30% when administered as Sandimmune®. 
Later, an improved formulation of cyclosporin A, Sandimmun Neoral® was 
commercialized. It is a microemulsion containing corn oil mono-, di- and tri-
glycerides, polyoxyl 40 hydrogenated castor oil, propylene glycol and DL-α-
tocopherol with cyclosporin A well dispersed within the mixture (Levy and Grant, 
1994). Upon dilution with an aqueous phase, this SEDDS formulation produces 
a fine and homogenous microemulsion with no precipitation of the incorporated 
cyclosporin A. Sandimmun Neoral® has been shown to increase the oral 
bioavailability of cyclosporin A by 40% to 60% (Kovarik et al., 1994) with less 
inter- and intra-subject variability in comparison with the earlier Sandimmune® 
product (Holt et al., 1994). 
 
1.3.2 ENHANCING THE ORAL BIOAVAILABILITY OF CYCLOSPORIN A 
Cyclosporin A has very low oral absorption due to its BCS Class II 
characteristics. Its low aqueous solubility limits the dissolution rate in the lumen. 
Therefore, many approaches have been used to improve the solubility and 
dissolution of cyclosporin A with the intention of enhancing its oral bioavailability. 
It has been suggested that the oral bioavailability of cyclosporin A can be 
enhanced by increasing the drug permeability through the intestinal membrane, 
improving drug solubilization and reducing droplet size (Gao et al., 1998). In 
most cases, drug solubilization effect could be increased by reducing the 
droplet size. Smaller droplet size means larger total surface area exposed 
which could lead to improvement in the drug dissolution. However, cyclosporin 
A nanospheres prepared by Ford et al. (1999) were shown to posses a relative 
bioavailability of only 3% compared to Sandimmun Neoral® although the size of 
the nanospheres prepared were within the range of 250 nm to 900 nm. 
 
Gao et al. (1998) reported on a formulation of a cyclosporin A microemulsion 
prepared by adding 20 mg cyclosporin A into 0.2 ml Oil-Smix mixture containing 
Cremophor EL, Transcutol P and Captex 355 at a ratio of 10:5:4. The 
microemulsion droplets formed were only 22 nm in size when diluted with an 
aqueous phase and has comparable oral bioavailability to Neoral® 
microemulsion formulation. The workers concluded that the enhancement of the 
bioavailability of cyclosporin A loaded in this microemulsion system might be 
due to the small droplet size of the microemulsion formed. 
 
Lecithin vesicles were proposed to be promising carriers in the oral delivery of 
cyclosporin A in another study (Guo et al., 2001). Cyclosporin A in lecithin 
vesicles were prepared by adding 0.375% w/w cyclosporin A and 4% w/w 
lecithin in a 1:1 mixture of methanol and chloroform. The oral bioavailability of 
cyclosporin A in the lecithin vesicles was compared to Sandimmun Neoral® 
using rabbits. The relative bioavailability of cyclosporin A lecithin vesicles 
versus Sandimmun Neoral® was 105 ± 21% (n = 6) and statistical analysis 
demonstrated that both preparations were bioequivalent. Therefore, the workers 
concluded that lecithin vesicles could facilitate the oral delivery of cyclosporin A, 
due to their absorption enhancement effect. Another formulation prepared by 
adding 3 mg/ml cyclosporin A in 2% egg lecithin and 10% soybean oil was 
reported by Kim et al. (2002). This oil-in-water emulsion showed comparable 
pharmacokinetics and pharmacodynamics to the commercial products 
(Sandimmun Neoral® and CIPOL Inj®). Nevertheless, the workers found that 
this formulation was more effective via oral administration than intravenous. 
 
 
 
There have been many other formulations reported for increasing the oral 
bioavailability of cyclosporin A using SEDDS. Cyclosporin A oral bioavailability 
from SEDDS formulations was found to be governed by a combination of 
different lipid excipients, ratio between lipid excipients and the percentage of 
drug incorporated (Odeberg et al., 2003). González et al. (2002) prepared a 
cyclosporin A self-emulsifying formulation by adding cyclosporin A into Solutol 
HS15:Labrafil M2125:oleic acid  (in a ratio of 7:2:1) to make a drug 
concentration of 100 mg/ml. This self-emulsifying formulation was shown to 
improve the oral bioavailability by 2-folds compared to a cyclosporin A 
microsuspension in rats. Moreover, Odeberg et al. (2003) successfully prepared 
a self-emulsifying drug delivery system based on natural lipid components 
[which consisted of 50% neutral lipids and 50% polar lipids (mixed 
phospholipids and galactolipids)] and medium-chain monoglycerides in a ratio 
of 1:1, with a cyclosporin A concentration of 10%. This formulation was 
bioequivalent with the Sandimmun Neoral® although the size of the emulsion 
dropets formed was nearly 100 times larger than that of Sandimmun Neoral®. 
 
1.4 SCOPE OF STUDY 
As reviewed above, Gelucire® which comprises a family of polyglycolized 
glycerides, has received acceptance as formulation excipient by the 
pharmaceutical industry. Among the members in the family, Gelucire® 44/14 
has been investigated for enhancing the solubility and bioavailability of lipophilic 
drugs. This commercially available excipient can disperse spontaneously in 
aqueous media and thus can be utilized in self-emulsifying formulations. 
Lipophilic drugs could be incorporated into Gelucire® 44/14 to form solid 
solution or solid dispersion. The ability of Gelucire® 44/14 to increase the 
solubility of lipophilic drugs is due to its amphiphilic properties. Lipophilic drugs 
will be bound to the lipophilic part of the fatty acids contained in Gelucire® 44/14, 
whereas the hydrophilic part of the fatty acids will facilitate the dissolution or 
dispersion of the matrices in the aqueous phase. Consequently, the drugs 
incorporated will dissolve or disperse together with the matrices. 
 
Thus, the aim of the present study was to investigate the potential of Gelucire® 
44/14 in enhancing the aqueous solubility and oral bioavailability of a model 
lipophilic drug with poor aqueous solubility. Cyclosporin A, a lipophilic 
polypeptide, was chosen as model drug in present study. Cyclosporin A is 
categorized as a BCS Class II drug wherein the oral absorption of the drug is 
limited by its solubility. The present study was conducted in various stages with 
the following objectives: 
1. To prepare and characterize self-emulsifying formulations of cyclosporin 
A using Gelucire® 44/14. 
2. To develop a liquid chromatography tandem mass spectrometry (LC-
MS/MS) method for determination of cyclosporin A in plasma samples. 
3. To evaluate the potential of Gelucire® 44/14 in enhancing the oral 
bioavailability of cyclosporin A in rats. 
 
Table1.1: Specification of Gelucire® bases (Craig, 1995) 
Type of 
gelucire 
Acid 
value 
Saponification 
value 
Hydroxyl 
value 
Iodine 
value 
Melting 
point, °C 
33/01 < 1 240 – 260 < 10 < 3 33 – 38 
35/10 < 2 120 – 135 70 – 90 < 2 29 – 34 
37/02 < 2 200 – 215 30 – 50 < 2 34.5 – 39.5 
37/06 < 2 165 – 180 100 – 120 < 2 30.5 – 35.5 
39/01 < 0.2 225 – 245 < 6 < 2 38 – 40 
42/12 < 2 95 – 115 30 – 50 < 2 41.5 – 46.5 
43/01 < 0.2 220 – 240 < 6 < 2 42 – 45 
44/14 < 2 75 – 95 30 – 50 < 2 42.5 – 47.5 
46/07 < 2 125 – 140 65 – 85 < 2 47 – 52 
48/09 < 2 105 – 125 60 – 80 < 2 46 – 51 
50/02 < 2 180 – 195 25 – 45 < 2 46.5 – 51.5 
50/13 < 2 65 – 80 30 – 50 < 2 46 – 51 
53/10 < 2 95 – 115 25 – 45 < 2 47.5 – 52.5 
54/02 < 6 175 – 195 80 – 120 < 3 53 – 57 
55/18 < 6 8 – 20 - < 3 54.5 – 58.5 
62/05 < 5 70 – 90 < 60 < 10 59 – 70 
64/02 < 2 165 – 185 80 – 120 < 3 63.5 – 67.5 
 
Table1.2: Distribution of fatty acids in Gelucire® 44/14 (Gattefossé, 1999) 
Fatty acid Chain length Distribution 
Caprylic acid 8 4 – 10 % 
Capric acid 10 3 – 9 % 
Lauric acid 12 40 – 50 % 
Myristic acid 14 14 – 24 % 
Palmitic acid 16 4 – 14 % 
Stearic acid 18 5 – 15 % 
 
